Of a series of carbocyclic analogs of adenosine, in which the ribose moiety was replaced by a cyclopentenyl ring, neplanocin A, or (-)-9-[trans-2, trans-3-dihydroxy-4-(hydroxymethyl)cyclopent-4-enyl]adenine proved particularly effective in inhibiting the multiplication of DNA viruses (i.e., vaccinia), (-)RNA viruses (i.e., parainfluenza, measles, and vesicular stomatitis), and double-stranded RNA viruses (i.e., reo) in vitro in cell culture. Depending on the cells used, the MIC of neplanocin A for these viruses ranged from 0.01 to 4 micrograms/ml, and depending on the parameter used to assess toxicity for the host cell, the specificity index of neplanocin A ranged from 50 to 4,000. As postulated before for other adenosine analogs, neplanocin A may owe its antiviral action to inhibition of S-adenosylhomocysteine hydrolase, hence perturbation of transmethylation reactions. In vivo, neplanocin A afforded only marginal protection against a lethal infection of mice with vesicular stomatitis virus.
Various non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been reported to specifically inhibit human immunodeficiency virus type 1 (HIV-1): for example, tetrahydroimidazobenzodiazepinone (TIBO), hydroxyethoxymethylphenylthiothymine (HEPT), dipyridodiazepinone (i.e. nevirapine), pyridinone, bis(heteroaryl)piperazine (BHAP), tert-butyldimethylsilylspiroaminooxathioledioxide (TSAO), α-anilinophenylacetamide (α-APA) and quinoxaline derivatives. These compounds interact allosterically (i.e. non-competitively with respect to the natural substrate (dNTPs)) with a specific non-substrate binding site ‘pocket’ of the HIV-1 reverse transcriptase (RT). The most potent NNRTIs have been found to inhibit HIV-1 replication at nanomolar concentrations. These compounds therefore offer great potential for the treatment of HIV-1 infections. Yet, the virus may rapidly develop resistance to these drugs. The mutations conferring resistance have been mapped at the RT positions 100 (Leu × lle), 103 (Lys × Asn), 106 (Val × Ala), 108 (Val × lle), 138 (Glu × Lys), 179 (Val × Asp), 181 (Tyr × Cys), 188 (Tyr × Cys/His), 190 (Gly × Glu) and 236 (Pro × Leu). However, these mutations do not necessarily lead to cross-resistance among the various NNRTIs, and, in some cases, they have proved to be mutually suppressive. Several strategies could be envisaged to circumvent or prevent the resistance problem: switching from one NNRTI (to which the virus has developed resistance) to another (to which the virus has not developed resistance); combining different RT inhibitors that do not confer cross-resistance, or that may, in fact, even counteract development of resistance to one another; and, using sufficiently high (‘knocking-out’) concentrations of the NNRTIs from the start, so as to completely shut down virus replication and prevent resistance from emerging. NNRTIs differ in several aspects from the 2,3-dideoxynucleoside (ddN) type of RT inhibitors. An obvious strategy to be further pursued in clinical trials is based upon the combination of NNRTIs with ddNs, as such combinations may offer synergistic anti-HIV activity, while reducing the risk or rate of resistance development.
Purpose This paper aims to present a possible complete set of dimensionless parameters to describe the process of selective laser melting (SLM). This makes it possible to compare the similarity between different experiments, a sine‐qua‐non for a correct comparison of the results. Design/methodology/approach The paper describes the application of dimensional analysis to SLM. Findings Although the idea of dimensionless numbers is far from new, it has apparently never been applied rigorously to rapid prototyping and rapid manufacturing technologies. The technique is important, since it reduces the number of factors and makes it possible to compare results of different research groups. Furthermore, some more fundamental insights about the process can be gained. Originality/value This work is a first step towards a manageable system to control very difficult processes.
No abstract is provided for this article.